Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 5von Hippel-Lindau Disease 2Neoplasm Metastasis 2Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroectodermal Tumors, Primitive 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1

Interventions

Bevacizumab 5pembrolizumab 3Paclitaxel 3fludarabine 2Sorafenib 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1erythromycin propionate-N-acetylcysteinate 1durvalumab 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1belzutifan 1aflibercept 1abiraterone 1Thalidomide 1Temozolomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × belzutifan × Genitourinary × Clear all
NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡